Digital men’s health platform Numan has raised £45m in new financing.
The firm behind memorable erectile dysfunction TV ads said the Series B round extension would help it to lead the next era of preventative, digital healthcare – including an expansion into female health – following its first full year of profitability in 2024.
It comprises a new £22m equity investment led by Big Pi Ventures and joined by Endeavor Catalyst as well as existing investors White Star Capital and Novator Partners.
The fundraise also includes access to £20m in growth capital from HSBC Innovation Banking.
Numan saw revenue more than double year-on-year to £67m by the end of 2024. To date, the company has now treated over 650,000 patients across obesity management, men’s health and diagnostics.
“Our latest funding is a testament to both our commercial performance and belief in our long-term vision for providing personalised, preventative health at scale,” said Sokratis Papafloratos, CEO.
“With the fresh conviction of Big Pi Ventures, Endeavor Catalyst and HSBC Innovation Banking – as well as the continued backing of White Star Capital and our long-term investors – we are now perfectly positioned to expand our reach, deepen our clinical capabilities, and accelerate innovation to help our patients live happier, healthier, longer lives.
“We started 2025 in a very strong position, one that allowed us to be genuinely choiceful about our next move. Over the past 18 months we’ve seen an explosion in demand – our patients have shown incredible engagement and achieved life-changing outcomes.
“This interest fuelled our growth and success in both reaching and maintaining profitability. That’s why we believe now is the time to invest in scaling what works and innovating for the future of healthcare.”
The funding will power Numan’s expansion into female health and help to deepen patient relationships through enhanced screening and preventative care programmes.
The firm said it will also go towards scaling the platform’s infrastructure to serve a growing patient base, expanding marketing efforts to reach more people in need, and advancing Numan’s AI-driven capabilities in a careful, clinically responsible manner.